Annual return of 118.79% - See How Click here now!
Forward Industries Inc. (NASDAQ: FORD | Quote | Chart | News | PowerRating) engages in the design, marketing, and distribution of carry solutions for hand held consumer electronics products. It offers carry cases for cell phone handsets, cases for handset camera attachments, handset plastic belt clips, carrying case straps and bags, decorative faceplates, wrist straps, digital display cleaning cloths, and other accessory products; and medical monitoring and diagnostic kit carrying cases. The company's product portfolio also includes belt clips, as well as other carry and storage solutions, including cases for cameras, MP3 players, and retail bar code scanners. Forward Industries sells its products to original equipment manufacturers, as well as to retailers and wholesalers of cellular phone products and related accessories. The company was founded in 1954 and is based in Pompano Beach, Florida. With 7.9 million shares outstanding and 437,700 shares declared short as of July 2008, there is a failure to deliver in shares of FORD. According to quarterly data provided by the SEC, there were still 36,673 shares of FORD that were failing-to-deliver as of September 27, 2007.
China Finance Online Co. Ltd. (NASDAQ: JRJC | Quote | Chart | News | PowerRating) through its subsidiaries, specializes in online financial, and listed company data and information operations in the People's Republic of China. It offers securities market information, technical analysis, and fundamental analysis services. The company also offers subscription-based services on a single information platform that integrates data and information from various sources with features and functions, such as data and information search, retrieval, delivery, storage, and analysis. It collects, processes, and provides financial analysis tools, historical data, news, research reports, and online forums to its subscribers in one integrated information platform, which allows them to make informed investment decisions with respect to various listed company stocks, bonds, and mutual funds. In addition, the company engages in storing content; serving as an integral part of its information platform; serving as download platforms for its service offerings; and displaying online advertisements. It serves individual investors managing their own money; professional investors, such as institutional investors managing money on behalf of their clients and high net worth individuals; and other financial professionals, including investment bankers, stock analysts, financial reporters, and middle class individuals. The company markets service offerings through its Websites, as well as through customer support personnel at its telemarketing and customer service centers. China Finance Online Co. was founded in 1998 and is based in Beijing, the People's Republic of China. With 19.73 million shares outstanding and 4.3 million shares declared short as of July 2008, there is a failure to deliver in shares of JRJC. According to quarterly data provided by the SEC, there were still 209,431 shares of JRJC that were failing-to-deliver as of September 28, 2007.
Optimer Pharmaceuticals Inc. (NASDAQ: OPTR | Quote | Chart | News | PowerRating) a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products. The company develops products that treat gastrointestinal infections and related diseases. Its two late-stage anti-infective product candidates include OPT-80, an antibiotic in two Phase III registration trials for the treatment of Clostridium difficile-infections/Clostridium difficile-associated disease, the common nosocomial diarrhea; and Prulifloxacin, an antibiotic in two Phase III trials for the treatment of infectious diarrhea in travelers, a community-acquired infection, which is caused by a range of bacteria. It also develops OPT-1068/CEM-101, a pre-clinical antibiotic against respiratory tract infections; an OPopS drug discovery platform; OPT-822, a carbohydrate-based immunostimulant therapy for the treatment of metastatic breast cancer that completed phase I trials; and OPT-88 as a disease-modifying intra-articular and as a therapy for osteoarthritis. The company has a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds. Optimer Pharmaceuticals was founded 1998 and is headquartered in San Diego, California. With 27.93 million shares outstanding and 1.91 million shares declared short as of July 2008, there is a failure to deliver in shares of OPTR. According to quarterly data provided by the SEC, there were still 64,675 shares of OPTR that were failing-to-deliver as of September 12, 2007.
China Pharma Holdings Inc. (OTCBB: CPHI | Quote | Chart | News | PowerRating) through its subsidiary, Hainan Helpson Medicine and Bio-Technology Co., Ltd., engages in the manufacture, marketing, and sale of pharmaceuticals in the People's Republic of China. The company offers various products, including Naprooxen Sodium and Pseudophedrine Hydrochloride sustained release tablets that are anti-flu medicines for the temporarily relief of cold, sinus, and flu symptoms; Bumetnide, a diuretics drag for the treatment of various edema diseases; Gastrodin Injection that is used for neurasthenia, neurasthenia syndrome, headache, vertigo, and traumatic; Hepatocyte Growth-promoting Factor for Injection that is used to assist and treat various heavy-duty virus hepatitis; and Propylgallate, which is used for preventing and treating cerebral thrombosis, coronary heart disease, and complication after the surgery-thrombus deep phlebitis. Its products also include Ozagrel Sodium that is used to treat acute cerebral infarction and kinesipathy accompanied by cerebral infarction; Alginic Sodium Diester Injection, which is used in ischemic heart and cerebrovascular diseases; Cerebroprotein Hydroloysate Injection that is for the improvement of the symptom of sequela of craniocerebral traumatism and cerebrovascular diseases; Buflomedil Hydrochloride for the treatment of peripheral blood vessel diseases; and Clarthromycin Granules and Clarthromycin Capsules, which are macrolide antibiotic drugs for the treatment of nasopharynx infection, lower respiratory tract infection, and skin tissue infection. In addition, the company offers Cefalexin Capsules for acute tonsillitis; and recombined human fibroblast growth factor that is used as a raw material for cosmetics. The company is based in Haikou, the People's Republic of China. With 37.28 million shares outstanding and 80,500 shares declared short as of July 2008, there is a failure to deliver in shares of CPHI.
Global Med Technologies Inc. (OTCBB: GLOB | Quote | Chart | News | PowerRating) designs, develops, markets, and supports information management software products for blood banks, hospitals, centralized transfusion centers, and other health care related facilities in the United States, Africa, Canada, and the Caribbean. Its products include SafeTrace, which is used to assist community blood centers, hospitals, plasma centers, and outpatient clinics for the collection and management of blood and blood products; SafeTrace Tx, a transfusion management information system designed for hospitals and centralized transfusion centers to enable the quality of blood transfused into patient-recipients; and ElDorado Donor, a blood management software application designed to provide the information system needs of blood banks and donor centers. The company, through its subsidiary, PeopleMed.com, Inc., (PeopleMed) develops a software application designed to provide HMO providers and other third party payers access to clinical information for chronic disease patients. PeopleMed supports chronic disease management as an application service provider and its system uses the Internet to co-ordinate sources of information and users of a patient's clinical information, including laboratory, pharmacy, primary and specialty care providers, claims, and medical records. Global Med Technologies also involves in licensing software; the provision of maintenance, consulting, and support services; and in the resale of software obtained from vendors. The company was founded in 1989 and is based in Lakewood, Colorado. With 26.94 million shares outstanding and 45,700 shares declared short as of July 2008, there is a failure to deliver in shares of GLOB. According to quarterly data provided by the SEC, there were still 223,646 shares of GLOB that were failing-to-deliver as of September 28, 2007.
Ampex Corp. (OTC: AMPXQ | Quote | Chart | News | PowerRating) together with its subsidiaries, engages in the development and licensing of visual information technology products. The company operates in two segments, Recorders and Licensing. The Recorders segment primarily engages in the sale and service of data acquisition and instrumentation recorders that record data and images rather than computer information; and mass data storage products consisting of 19-millimeter scanning recorders and robotic library systems, as well as related tape and after-market parts. The Licensing segment involves in the licensing of its intellectual property to manufacturers of consumer digital video products. Ampex Corporation also holds patents and patent applications covering digital image-processing, data compression, and recording technologies. In addition, it develops and incorporates technology in the design and manufacture of instrumentation recorders primarily for use in defense applications to gather digital images and other data from aircraft, satellites, and submarines, as well as for in flight and sensor test applications. The company distributes its products directly through its internal sales force, as well as through independent value-added resellers. Ampex Corporation sells its products and services in the United States, Europe, Africa, the Middle East, and Japan. Ampex Corporation was founded in 1944 and is headquartered in Redwood City, California. On March 30, 2008, Ampex Corp., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of New York. With 3.90 million shares outstanding and 165,000 shares declared short as of July 2008, there is a failure to deliver in shares of AMPXQ.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,150,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
